Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Items 401–500 of 680
The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies
Zabłocki, K., & Górecki, D. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119434 · Cited by 12
“This has a negative impact on treatment efficacy [100] and is potentially dangerous.”
BackgroundHayashita‐Kinoh, H., Posadas-Herrera, G., Nitahara‐Kasahara, Y., Kuraoka, M., Okada, H., Chiyo, T., Takeda, S., & Okada, T. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.003 · Cited by 11
“5-minidystrophin in six DMD patients, in which T cell responses to transduced dystrophin were detected.(13) To overcome these responses against vectors or transgenes, we previously reported that a combination of tolerance induction against rAAV followed by a single intravenous injection of rAAV-microdystrophin into th…”
Aliphatic Quaternary Ammonium Functionalized Nanogels for Gene Delivery
Zhang, H., Keskin, D., de Haan-Visser, W. H., Zu, G., van Rijn, P., & Zuhorn, I. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111964 · Cited by 12
Recombinant Adeno-Associated Viral Vector Reference Standards
Moullier, P., & Snyder, R. O. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00015-6 · Cited by 11
Parker, M. H., Loretz, C. J., Tyler, A. E., Snider, L. D., Storb, R. F., & Tapscott, S. J. (2012) · Skeletal Muscle · doi:10.1186/2044-5040-2-4 · Cited by 10
“Specifically, studies of gene therapy in cxmd canines revealed an unexpected immune reaction not observed in mice, which appears to be recapitulated in DMD patients [32].”
BackgroundTruncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00573-1 · Cited by 11
Zhang, P., Luo, X., Bird, A., Li, S., & Koeberl, D. D. (2012) · BioResearch open access · doi:10.1089/biores.2012.0217 · Cited by 12
“Indeed, gene therapy with adeno-associated virus (AAV) vectors has yielded proof-ofconcept in many preclinical experiments and advanced to clinical trials in Duchenne muscular dystrophy (DMD).1 However, unanticipated T cell responses directed against AAV vector-mediated expression of dystrophin have complicated the cl…”
BackgroundMethodInfluentialDuchenne Muscular Dystrophy (DMD) Protein-Protein Interaction Mapping.
Rezaei–Tavirani, M., Okhovatian, F., Azodi, M. Z., & Tavirani, M. R. (2017) · Iranian journal of child neurology. · doi:10.22037/ijcn.v11i4.15220 · Cited by 10
Zschüntzsch, J., Jouvenal, P., Zhang, Y., Klinker, F., Tiburcy, M., Liebetanz, D., Malzahn, D., Brinkmeier, H., & Schmidt, J. (2020) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12569 · Cited by 10
Gene editing and modulation for Duchenne muscular dystrophy
Stephenson, A. A., & Flanigan, K. M. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.029 · Cited by 13
Han, X., Han, J., Wang, N., Ji, G., Guo, R., Li, J., Wu, H., Ma, S., Fang, P., & Song, X. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.891670 · Cited by 10
“Therefore, exploring potential diagnostic biomarkers and characterizing the infiltration pattern of immune cells in DMD is of great significance to enhance the diagnosis and prognosis of DMD (Mendell et al., 2010).”
BackgroundSelf-citationMuscular Dystrophies and Cancer Cachexia: Similarities in Chronic Skeletal Muscle Degeneration
Berardi, E. (2017) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk2040039 · Cited by 10
Autoimmunity in a Genetic Disease — A Cautionary Tale
Moore, M. J., & Flotte, T. R. (2010) · New England Journal of Medicine · doi:10.1056/nejme1009056 · Cited by 10
Lek, A., Atas, E., Lin, B. L., Hesterlee, S. E., Abbott, J. K., Byrne, B. J., & Bönnemann, C. G. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-240002 · Cited by 10
“Software-guided approaches were used to redesign three human dystrophin epitopes previously identified as particularly immunogenic [16] – and confirmed by recent events in the DMD clinical trials.”
Self-Reactive CFTR T Cells in Humans: Implications for Gene Therapy
Calcedo, R., Uta Griesenbach, D., Dorgan, D. J., Soussi, S., Boyd, A., Davies, J. C., Higgins, T., Hyde, S. C., Gill, D. R., Innes, J. A., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2012.249 · Cited by 9
“The investigators monitored these subjects closely after gene therapy and noted that one of them went on to respond to gene therapy with a clear T cell response to the transgene product (Mendell et al., 2010).”
InfluentialBuilding immune tolerance through DNA vaccination
Parks, R. J., & Gussoni, E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813461115 · Cited by 9
Durbacz, M. Z., Zhang, Y. L., Li, H., Nishiyama, T., Ortiz, E. S., McAnally, J., Alzhanov, D., Liu, N., & Olson, E. N. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102569 · Cited by 9
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
Okada, H., Ishibashi, H., Hayashita‐Kinoh, H., Chiyo, T., Nitahara‐Kasahara, Y., Baba, Y., Watanabe, S., Takeda, S., & Okada, T. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.21 · Cited by 9
Mesenchymal Stem Cells for Regenerative Medicine for Duchenne Muscular Dystrophy
Elhussieny, A., Nogami, K., Sakai‐Takemura, F., Maruyama, Y., Abdelbakey, A. O., El-Kheir, W. A., Takeda, S., & Miyagoe‐Suzuki, Y. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92824 · Cited by 8
“In a clinical trial of gene therapy using a dystrophin transgene, T cells specific to epitopes of pre-existing dystrophin in revertant fibres were detected, suggesting the existence of autoreactive T-cell immunity against dystrophin before treatment [71].”
BackgroundGao, S., Chen, S. N., Nardo, C. D., & Lombardi, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00834 · Cited by 8
“The autoimmune response was induced by epitopes contained in the truncated dystrophin encoded by the endogenous gene after spontaneous in-frame splicing (Mendell et al., 2010).”
BackgroundMolecular targets to treat muscular dystrophies
Kinter, J., & Sinnreich, M. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13916 · Cited by 13
Savino, W., Mariz, F. P., & Mouly, V. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7374-3_16 · Cited by 8
Limback, K. A., Jacobus, W. D., Wiggins-McDaniel, A., Newman, R., & White, R. A. (2022) · Biotechnology Journal International · doi:10.9734/bji/2022/v26i6662 · Cited by 8
Lyu, P., Yadav, M., Yoo, K. W., Jiang, C., Li, Q., Atala, A., & Lu, B. (2024) · Gene Therapy · doi:10.1038/s41434-024-00490-w · Cited by 8
Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy?
Górecki, D. C., Kaliński, P., & Pomeroy, J. (2025) · Gene Therapy · doi:10.1038/s41434-025-00531-y · Cited by 9
“2), which leads to elimination of transgene-expressing cells, cessation of the therapeutic effect [33, 36], and initiating additional tissue damage (e.g., myositis).”
InfluentialExogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver
González-Moreno, L., Santamaría-Cano, A., Paradela, A., Martínez‐Chantar, M. L., Martín, M. A., Pérez-Carreras, M., Picazo, A. G., Vázquez, J., Calvo, E., González‐Aseguinolaza, G., et al. (2023) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2023.100967 · Cited by 11
“It is not known whether the immune system of the patient may react to the recombinant gene product [20,21,26,27].”
BackgroundCasey, G., Askew, C., Brimble, M. A., Samulski, R. J., Davidoff, A. M., Li, C., & Walters, B. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242599 · Cited by 7
Self-citationEfficient AAV Vector Production System: Towards Gene Therapy For Duchenne Muscular Dystrophy
Okada, T. (2013) · InTech eBooks · doi:10.5772/53023 · Cited by 7
“Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle.[56] The potential for T-cell immuni‐ ty to self and non-self dystrophin epitopes should be considered in designing and monitor‐ ing experimental…”
BackgroundMolecular Therapies for Muscular Dystrophies
Lin, A. Y., & Wang, L. H. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0509-2 · Cited by 7
Ethical issues in neurogenetic disorders
Kang, P. B. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53501-6.00022-6 · Cited by 7
A novel decoding strategy for ProteinMPNN to design with less visibility to cytotoxic T-lymphocytes
(2025) · doi:10.1016/j.csbj.2025.07.055 · Cited by 6
“In particular, as AI-designed intra-cellular protein therapeutics incorporate novel functions and diverge from native sequences, they may be increasingly recognized by CTLs, potentially reducing efficacy or triggering autoimmune responses, as seen in cases of anti-transgene immunity [2,3].”
The Promise and Pitfalls of AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy
Kurshakova, E. V., Levchenko, O. A., Smirnikhina, S., & Лавров, А. В. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121058 · Cited by 6
“Similar results were found in a patient with deletion of exons 3–17 [103].”
Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis
Spathis, R., Kuriplach, D. R., Narvesen, S., Eybs, M., Huang, K., Torres, S., King, M., Bagley, E., Elustondo, P. A., Lawlor, M. W., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1527840 · Cited by 6
“Dystrophin replacement by gene therapy triggers an anti-dystrophin immune response in DMD patients and animal models that likely limits the long-term ef fi cacy of this treatment (3 – 5 , 27).”
Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities
Belova, L., Лавров, А. В., & Smirnikhina, S. (2022) · BioEssays · doi:10.1002/bies.202200055 · Cited by 6
“[67–71] In clinical studies of drugs utilizing rAAV vectors, a transgenic immune response was observed in several cases after intramuscular injection of the vectors,[72,73] but despite this, longterm expression of the transgene was recorded in the majority of patients.”
BackgroundThe P2X7 purinoceptor in pathogenesis and treatment of dystrophino- and sarcoglycanopathies
Górecki, D. C., & Rumney, R. M. H. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102357 · Cited by 6
Huang, X., Wang, X., Li, L., Qizhao, W., Xu, W., Wu, W., Xie, X., & Diao, Y. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17858 · Cited by 6
Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy
Singh, S., Singh, T., Kunja, C., Dhoat, N. S., & Dhania, N. K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174568 · Cited by 7
Meng, J., Moore, M., Counsell, J. R., Muntoni, F., Popplewell, L. J., & Morgan, J. E. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.015 · Cited by 6
“However, the potential immune response against the full-length dystrophin will still need to be considered, especially for patients with large deletions or with deletions removing specific protein domains.(62) This may be lessened by the incorporation of a muscle-specific promotor to limit dystrophin expression to mus…”
BackgroundFlanigan, K. M., Campbell, K., Viollet, L., Wang, W., Gomez, A. M., Walker, C. M., & Mendell, J. R. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.092 · Cited by 6
Self-citationRamalho, T. C., de Castro, A. A., Tavares, T. S., Silva, M. D. C., Silva, D. R., Cesar, P. H., Santos, L. D. A., da Cunha, E. F. F., Nepovimová, E., & Kuča, K. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.06.011 · Cited by 6
“Although good results were found in animal templates, the human investigations did not achieve success because of probable autoimmunity to dystrophin (Mendell et al., 2010).”
BackgroundEffect of AAV9-hIGF-1 on inflammatory reaction in mdx mice and its mechanism.
Ji, G., Sun, S., Wu, H., Chen, X., Cui, H., Tang, J., Lu, S., Lu, Y., Li, D., & Song, X. (2020) · PubMed · Cited by 6
Progressive muscular dystrophies
Kitaeva, V. E., Котов, А. С., & Бунак, М. С. (2021) · Russian neurological Journal · doi:10.30629/2658-7947-2021-26-2-43-57 · Cited by 6
HIV-Derived Vectors for Gene Therapy Targeting Dendritic Cells
Rossetti, M. M., Cavarelli, M., Gregori, S., & Scarlatti, G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4433-6_9 · Cited by 6
Autoimmunity, Recessive Diseases, and Gene Replacement Therapy
Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.253 · Cited by 6
A novel decoding strategy for ProteinMPNN to design with less MHC Class I immune-visibility
Gasser, H.-C., Rajan, A., & Alfaro, J. A. (2025) · doi:10.1101/2025.04.14.648837 · Cited by 6
Childhood muscular dystrophies
Younger, D. S. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00024-8 · Cited by 5
Novel Targets and Approaches to Treating Skeletal Muscle Disease
McNally, E. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00081-8 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Qiao, C., Li, C., Zhao, C., Li, J., Bian, T., Grieger, J. C., Li, J., Samulski, R. J., & Xiao, X. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.176 · Cited by 5
“Because high vector doses are often required in large animals (Kornegay et al., 2010) and eventually in human patients (Mendell et al., 2010), improvement in every step of gene transfer process counts.”
BackgroundSelf-citationConsiderations on Preclinical Neuromuscular Disease Gene Therapy Studies
Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_17 · Cited by 6
Targeted Treatments for Inherited Neuromuscular Diseases of Childhood
Fay, A. J., Knox, R. N., Knierbein, E. E. N., & Strober, J. B. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1702940 · Cited by 5
A Spotlight on T Lymphocytes in Duchenne Muscular Dystrophy—Not Just a Muscle Defect
Coles, C. A., Woodcock, I. R., Pellicci, D. G., & Houweling, P. J. (2022) · Biomedicines · doi:10.3390/biomedicines10030535 · Cited by 5
“These revertant dystrophin-myofibres expressed functional, truncated epitopes of dystrophin recognized by auto-reactive T cells [36].”
BackgroundRegenerative Rehabilitation for Duchenne Muscular Dystrophy
Swiderski, K., Hardee, J. P., & Lynch, G. S. (2022) · Physiology in health and disease · doi:10.1007/978-3-030-95884-8_4 · Cited by 5
Gene therapy, an ongoing revolution
Benvéniste, O. (2012) · Blood · doi:10.1182/blood-2012-02-409086 · Cited by 5
Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy
Gowran, A., Brioschi, M., Rovina, D., Chiesa, M., Piacentini, L., Mallia, S., Banfi, C., Pompilio, G., & Santoro, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168954 · Cited by 5
Sarnat, H. B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00601-1 · Cited by 5
Fang, P., Han, J., An, D., Bu, Y., Ji, G., Liu, M., Deng, J., Guo, M., Han, X., Wu, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429609 · Cited by 4
A humanized Gs-coupled DREADD for circuit and behavior modulation
Zhang, Q., Wang, R., Zhang, L., Li, M., Lin, J., Lu, X., Tian, Y., Lin, Y., Liu, T., Chen, Y., et al. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1577117 · Cited by 4
Gene therapy in Duchenne muscular dystrophy
Laugel, V. (2025) · Archives de Pédiatrie · doi:10.1016/s0929-693x(25)00254-4 · Cited by 4
Assessment of Immune Responses Against AAV Encoded Transgene Products
Gorovits, B., Azadeh, M., Fiscella, M., Harrison, T., Hofer, M., Janetzki, S., Jawa, V., Long, B. R., Lu, Y., Mahnke, Y. D., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-025-01192-w · Cited by 5
“…to TP have been linked to the reduction of transgene protein expression due to destruction of AAV transduced target-cells as, for example, observed in muscle-directed gene therapy studies investigating treatment of Duchene Muscular Dystro-phy utilizing AAV vector encoding mini-dystrophin (22, 23).”
InfluentialPesco, M. T., Öztürk, G. Z., Bhadola, S., Chrzanowski, S. M., Gushchina, L. V., & D'Ambrosio, E. S. (2026) · Muscles · doi:10.3390/muscles5010021 · Cited by 4
“Patients with pre-existing neutralizing antibodies to the specific AAV serotype are usually excluded from clinical trials, as pre-existing immunity can prevent effective transgene delivery and increase safety risks [42,43].”
CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy
Ralu, M., Guiraud, S., Dastidar, S., Galbiati, P., Sadaoui, E., Mazed, F., Amor, F., Cian, A. D., Richard, I., Mamchaoui, K., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.025 · Cited by 4
“In addition, dystrophin-directed immune response was observed in some patients, 20–22 questioning the safety and longevity of such strategies.”
(2024) · doi:10.1016/j.immuno.2024.100035 · Cited by 4
Mayer-Hamblett, N., Kerper, N. R., Clancy, J. P., Davies, J. C., Taylor‐Cousar, J. L., Donaldson, S. H., Bell, S. C., Jain, R., Simmonds, N. J., Mall, M. A., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00206-1 · Cited by 5
Histological and Biochemical Evaluation of Muscle Gene Therapy
Lawlor, M. W., Schneider, J., Childers, M. K., & Brown, K. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_12 · Cited by 4
Overview of muscular dystrophy, it’s types, symptoms, management and possible treatment
Liaqat, S. T. (2022) · Pure and Applied Biology · doi:10.19045/bspab.2023.120028 · Cited by 4
Signs of Progress in Gene Therapy for Muscular Dystrophy Also Warrant Caution
Stedman, H. H., & Byrne, B. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.307 · Cited by 4
Song, Y., Rosenblum, S. T., Morales, L., Petrov, M., Greer, C. D., Globerman, S., & Stedman, H. H. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00776.2016 · Cited by 4
“Early efforts to ameliorate the phenotype by stem cell or gene replacement therapy revealed unanticipated challenges in therapeutic delivery (5, 25, 26, 33, 44).”
BackgroundBrunetti‐Pierri, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00030-7 · Cited by 5
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Self-citationChallenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 6
“[84] Mendell JR, Campbell K, Rodino-Klapac L et al.”
BackgroundCurrent Strategies of Muscular Dystrophy Therapeutics: An Overview
Lim, K. R. Q., & Yokota, T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2772-3_1 · Cited by 4
The advances and challenges of Gene Therapy for Duchenne Muscular Dystrophy
Tremblay, J. P. (2017) · Journal of Genetic Medicine and Gene Therapy · doi:10.29328/journal.jgmgt.1001003 · Cited by 6
“The test did not improve the condition of the patients and an immune reaction was observed against the transgene and the viral vector [9].”
BackgroundGene Therapy Today and Tomorrow
Lundstrom, K. H. (2019) · Diseases · doi:10.3390/diseases7020037 · Cited by 7
“Likewise, limited transgene expression was observed in limb girdle muscular dystrophy (LGMD) patients intramuscularly injected with AAV1 expressing γ-sarcoglycan and AAV expressing the mini-dystrophin gene administered to Duchenne muscular dystrophy (DMD) patients [68].”
BackgroundSárközy, A., Bushby, K. M. D., & Mercuri, E. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00134-8 · Cited by 4
Gene Therapy for Duchenne Muscular Dystrophy
van Putten, M., & Aartsma-Rus, A. M. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025029 · Cited by 4
Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 7
“Anti-transgene immune responses were documented in the clinical trials, mostly after intramuscular delivery of AAV vectors (108, 109).”
InfluentialReframing fibrosis as a barrier to regeneration and gene delivery in muscular diseases
Kılıç, H. B., & Kocaefe, Ç. (2026) · FEBS Journal · doi:10.1111/febs.70427 · Cited by 3
“…of a patient with limb-girdle muscular dystrophy 2D (LGMD2D), who was enrolled in a clinical trial involving sarcoglycan alpha (SGCA) gene replacement using the AAVrh74 vector [15], has renewed concerns about the safety of viral vector-based therapies, echoing setbacks seen two decades ago [19,20].”
Reinhard, J. R., Lin, S., Maino, E., Ham, D. J., & Rüegg, M. A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.041 · Cited by 6
“13–16 In LAMA2 MD, severe early-onset cases present with extensive inflammatory infiltration, 17–19 which may exacerbate immune responses to exogenous proteins, particularly bacterial components, such as Cas9 or split-intein domains, used in gene editing or dual-vector strategies.”
Sarcolipin Knockdown Therapy for Duchenne Muscular Dystrophy
Mareedu, S., Dwivedi, S., Niranjan, N., & Babu, G. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_23 · Cited by 3
Huang, X., Wang, X., Feng, L., Zhou, R., Chen, W., Jiang, X., Lv, F., Xu, W., Xu, X., Xie, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123742 · Cited by 3
Effect of m6A Recognition Protein YTHDC1 on Skeletal Muscle Growth
Huang, H., Lu, G., Xiao, L., Tan, B., Yang, Y., Hong, L., Li, Z., Cai, G., & Gu, T. (2025) · Animals · doi:10.3390/ani15131978 · Cited by 3
“Current therapeutic strategies primarily focus on inducing SE in the DMD gene to restore functional dystrophin [57], with SE of exons 44 or 45 shown to downregulate atrophy-related proteins and alleviate symptoms [55,58].”
Drug Discovery Approaches for Rare Neuromuscular Diseases
Wynne, G. M., & Russell, A. J. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00257 · Cited by 3
Therapeutic Gene Editing in Muscles and Muscle Stem Cells
Tabebordbar, M., Cheng, J. K. W., & Wagers, A. J. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_10 · Cited by 3
“…continued presence of vector genomes, possibly due to pre-existing or acquired T cell-mediated immune responses to dystrophin epitopes or AAV capsid proteins (see below), disease-associated inflammatory responses, CMV promoter silencing, or low AAV tropism (Bowles et al. 2012; Mendell et al. 2010).”
BackgroundResultLi, H., Xiao, L., Wang, L., Lin, J., Luo, M., Chen, M., He, R., Zhu, Y., & Zhang, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00970 · Cited by 4
“Several studies have indicated that the T cells involved in these inflammatory processes react specifically to dystrophin peptides presented by class I and II MHCs expressed on revertant myofibers (31, 32).”
BackgroundOya, R., Tsukamoto, O., Hitsumoto, T., Nakahara, N., Okamoto, C., Matsuoka, K., Kato, H., Inohara, H., & Takashima, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031747 · Cited by 3
“CMV promotor was employed because of its ability to express a cloned gene in the skeletal muscle via intramuscular injection of AAV [32].”
Dystrophin immunogenicity and requirement in myogenic cells: Paradigm shift in gene therapy for DMD
Górecki, D. C. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1122 · Cited by 3
On the path to evidence-based therapy in neuromuscular disorders
Younger, D. S. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00007-8 · Cited by 3
Abnormal Muscle Pathology and Physiology
Bogdanovich, S., Gardner, B. B., & McNally, E. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800040-3.00004-2 · Cited by 3
Gene Therapy of Skeletal Muscle Disorders Using Viral Vectors
Arnett, A. L. H., Ramos, J. N., & Chamberlain, J. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00076-4 · Cited by 3
Removing the Immune Response From Muscular Dystrophy Research
Chamberlain, J. S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.209 · Cited by 3
Cardiac Complications of Neuromuscular Disorders
Spurney, C. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00003-7 · Cited by 3
Gene Therapy Clinical Trials for Duchenne and Limb Girdle Muscular Dystrophies: Lessons Learned
Mendell, J. R., Rodino‐Klapac, L. R., & Walker, C. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_41 · Cited by 3
Self-citationMuscular Dystrophy Therapy Using Viral Vector-based CRISPR/Cas
Choi, E., & Koo, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_4 · Cited by 3
Mendell, J. R. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.003 · Cited by 3
Self-citationGene Editing for the Heart: Correcting Dystrophin Mutations
McNally, E. M. (2017) · Circulation Research · doi:10.1161/circresaha.117.311865 · Cited by 3
Functional mRNA delivery to hematopoietic stem and progenitor cells in vivoPreprint
Álvarez, D., Masse‐Ranson, G., Sedimbi, S. K., Wisti, P., Rodriguez, L., Santana, J., Manning, T., Towner, T., Geilich, B., Mihai, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.15.520650 · Cited by 4
Recent advances in Duchenne muscular dystrophy
Davies, K. E., & Perkins (2012) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s26637 · Cited by 4
Nordin, J. Z., & Aoki, Y. (2019) · The Journal of Pathology · doi:10.1002/path.5327 · Cited by 2
“T-cell immunity to viral and de novo dystrophin epitopes after gene transfer with adeno-associated virus (AAV) vectors have been reported [3].”
BackgroundIn Vivo Genome Engineering for the Treatment of Muscular Dystrophies
Kustermann, M., Rok, M. J., Cohn, R. D., & Ivakine, E. A. (2020) · Current Stem Cell Reports · doi:10.1007/s40778-020-00173-3 · Cited by 2
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.